Prognostic value of PAX3/7–FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis

Weiss, 2008, Rhabdomyosarcoma, 595 Weihkopf, 2008, Incidence and time trends of soft tissue sarcomas in German children 1985–2004 – a report from the population-based German Childhood Cancer Registry, Eur J Cancer, 44, 432, 10.1016/j.ejca.2007.11.013 Meza, 2006, Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group, J Clin Oncol, 24, 3844, 10.1200/JCO.2005.05.3801 Raney, 2001, Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V, J Pediatr Hematol Oncol, 23, 215, 10.1097/00043426-200105000-00008 Stevens, 2005, Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology – SIOP Malignant Mesenchymal Tumor 89, J Clin Oncol, 23, 2618, 10.1200/JCO.2005.08.130 Scrable, 1989, Molecular differential pathology of rhabdomyosarcoma, Genes Chromosomes Cancer, 1, 23, 10.1002/gcc.2870010106 Barr, 1993, Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma, Nat Genet, 3, 113, 10.1038/ng0293-113 Davis, 1994, Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma, Cancer Res, 54, 2869 Slater, 2007, Clinical relevance of molecular genetics to paediatric sarcomas, J Clin Pathol, 60, 1187, 10.1136/jcp.2006.040113 Fredericks, 1995, The PAX3–FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3, Mol Cell Biol, 15, 1522, 10.1128/MCB.15.3.1522 Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, PLoS Med, 6, 10.1371/journal.pmed.1000100 Parmar, 1998, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Stat Med, 17, 2815, 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8 Williamson, 2002, Aggregate data meta-analysis with time-to-event outcomes, Stat Med, 21, 3337, 10.1002/sim.1303 Tierney, 2007, Practical methods for incorporating summary time-to-event data into meta-analysis, Trials, 8, 16, 10.1186/1745-6215-8-16 Stang, 2010, Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses, Eur J Epidemiol, 25, 603, 10.1007/s10654-010-9491-z Liu, 2013, A step-by-step guide to the systematic review and meta-analysis of diagnostic and prognostic test accuracy evaluations, Br J Cancer, 108, 2299, 10.1038/bjc.2013.185 Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, Br Med J, 315, 629, 10.1136/bmj.315.7109.629 Kelly, 1997, Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma, J Clin Oncol, 15, 1831, 10.1200/JCO.1997.15.5.1831 Sorensen, 2002, PAX3–FKHR and PAX7–FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group, J Clin Oncol, 20, 2672, 10.1200/JCO.2002.03.137 Davicioni, 2006, Identification of a PAX–FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas, Cancer Res, 66, 6936, 10.1158/0008-5472.CAN-05-4578 Stegmaier, 2011, Prognostic value of PAX–FKHR fusion status in alveolar rhabdomyosarcoma: a report from the cooperative soft tissue sarcoma study group (CWS), Pediatr Blood Cancer, 57, 406, 10.1002/pbc.22958 Missiaglia, 2012, PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification, J Clin Oncol, 30, 1670, 10.1200/JCO.2011.38.5591 Anderson, 2001, UK Children's Cancer Study Group (UKCCSG) and the UK Cancer Cytogenetics Group. Detection of the PAX3–FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?, Br J Cancer, 85, 831, 10.1054/bjoc.2001.2008 Kazanowska, 2007, PAX3–FKHR and PAX7–FKHR fusion genes impact outcome of alveolar rhabdomyosarcoma in children, Fetal Pediatr Pathol, 26, 17, 10.1080/15513810701394702 Heerema-McKenney, 2008, Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype, Am J Surg Pathol, 32, 1513, 10.1097/PAS.0b013e31817a909a Eguía-Aguilar, 2010, Detection of fusion genes in formalin-fixed paraffin-embedded tissue sections of rhabdomyosarcoma by RT-PCR and fluorescence in situ hybridization in Mexican patients, Arch Med Res, 41, 119, 10.1016/j.arcmed.2010.02.005 Williamson, 2010, Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma, J Clin Oncol, 28, 2151, 10.1200/JCO.2009.26.3814 Dumont, 2012, PAX3/7–FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization, J Cancer Res Clin Oncol, 138, 213, 10.1007/s00432-011-1089-7 Skapek, 2013, PAX–FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report, Pediatr Blood Cancer, 60, 1411, 10.1002/pbc.24532 Wachtel, 2004, Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1, Cancer Res, 64, 5539, 10.1158/0008-5472.CAN-04-0844 Laé, 2007, Global gene expression profiling of PAX–FKHR fusion-positive alveolar and PAX–FKHR fusion-negative embryonal rhabdomyosarcomas, J Pathol, 212, 143, 10.1002/path.2170 Arndt, 2009, Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803, J Clin Oncol, 27, 5182, 10.1200/JCO.2009.22.3768 Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat Med, 21, 1539, 10.1002/sim.1186 Higgins, 2011 Stegmaier, 2012, Questionable universal validity of PAX3/FOXO1 fusion gene status as molecular marker for improvement of risk stratification in rhabdomyosarcoma therapy, J Clin Oncol, 30, 4039, 10.1200/JCO.2012.43.5628